ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. Two of its antiviral candidates for treating hepatitis B include Phase 2a clinical candidate TXL, a novel, highly potent analog of the successful antiviral drug tenofovir that has demonstrated the potential for low, once a day dosing compared to Viread and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against hepatitis B virus. ContraVir’s third candidate and lead clinical drug, Valnivudine, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is currently in Phase 3 clinical development. In addition to direct antiviral activity, Valnivudine has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study.

Show more
Edison, US
Size (employees)
14 (est)
ContraVir Pharmaceuticals was founded in 2013 and is headquartered in Edison, US
Report incorrect company information

ContraVir Pharmaceuticals Office Locations

ContraVir Pharmaceuticals has offices in Doylestown, Edmonton and Edison
Edison, US (HQ)
399 Thornall St
Doylestown, US
3805 Old Easton Rd
Edmonton, CA
2011 94 St NW
Show all (3)
Report incorrect company information

ContraVir Pharmaceuticals Financials and Metrics

ContraVir Pharmaceuticals Financials


Net income (Q1, 2018)

(2.7 m)

EBIT (Q1, 2018)

(3.9 m)

Market capitalization (14-Jun-2018)

16.6 m

Closing share price (14-Jun-2018)


Cash (31-Mar-2018)

4 m
ContraVir Pharmaceuticals's current market capitalization is $16.6 m.
USDFY, 2014FY, 2015FY, 2016

General and administrative expense

5.8 m

R&D expense

15 m

Operating expense total

20.8 m


(140.2 k)(14 m)(20.8 m)
USDQ1, 2016Q2, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2018

General and administrative expense

1.1 m1.5 m1.7 m1.7 m2 m1.9 m1.6 m

R&D expense

3.8 m4 m3.1 m4.3 m2.9 m4 m2.3 m

Operating expense total

4.8 m5.5 m4.9 m6 m4.9 m5.8 m3.9 m

Depreciation and amortization

6 k
USDFY, 2014FY, 2015FY, 2016FY, 2017


1.8 m4.6 m7.4 m6 m

Accounts Receivable


Current Assets

2 m5.2 m7.9 m6.1 m
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2018


3 m10.6 m6.1 m8.8 m4 m

Current Assets

3.6 m10.9 m6.6 m8.9 m4.1 m


73.8 k80 k71.6 k61.6 k46.4 k


1.9 m1.9 m1.9 m1.9 m1.9 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(140.5 k)(14.3 m)(17 m)

Depreciation and Amortization

16.4 k21.5 k

Accounts Payable

3.1 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

(4.8 m)(3 m)(4.8 m)(4.5 m)(7.6 m)(2.7 m)

Depreciation and Amortization

4.9 k

Accounts Payable

213.3 k114.4 k1.3 m3.2 m3.2 m3.4 m4.4 m2.3 m1.6 m146 k

Cash From Operating Activities

(3.6 m)
USDY, 2018

Financial Leverage

3.1 x
Show all financial metrics
Report incorrect company information

ContraVir Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

ContraVir Pharmaceuticals News and Updates

Report incorrect company information